Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
As choline transport and phosphorylation are upregulated in most cancers, including prostate
cancer, positron emission tomography (PET) with choline tracers has found widespread use to
detect recurrent disease. However, choline metabolism is not increased in a significant
number of cases, probably explaining why this imaging method has been reported to be weakly
sensitive and specific fro the detection of prostate cancer lesions, especially at low
prostate-specific antigen (PSA) levels. By contrast, prostate-specific membrane antigen
(PSMA) is overexpressed in most prostate cancer, suggesting that 68Ga-labelled PSMA ligands
could be superior to choline tracers. A meta-analysis published in 2016 (Perera M. and al.),
which included 18 studies, of which five reported histolopathologic correlation data for
68Ga-PSMA PET-positive lesions, indicated favourable sensitivity and specificity profiles of
68Ga-labelled PSMA ligands compared to choline-based PET imaging techniques.
Phase:
Phase 3
Details
Lead Sponsor:
Central Hospital, Nancy, France
Collaborators:
Advanced Nuclear Medicine Ingredients (ANMI) GIE NANCYCLOTEP